StockData

KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.26−0.17 (-4.96%)

Close on Nov 18, 2026Market cap $63.05MP/E –Yield –

Kala Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kala Bio's operating income for the twelve months ending Jun 30, 2026 was -$20.99M. For fiscal 2025 it was -$39.16M. The highest annual figure on record is -$15.95M in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$39.16M–
FY2024Dec 31, 2024-$40.98M–
FY2023Dec 31, 2023-$39.66M–
FY2022Dec 31, 2022-$81.71M–
FY2021Dec 31, 2021-$130.25M–
FY2020Dec 31, 2020-$96.23M–
FY2019Dec 31, 2019-$88.22M–
FY2018Dec 31, 2018-$64.72M–
FY2017Dec 31, 2017-$39.88M–
FY2016Dec 31, 2016-$32.67M–
FY2015Dec 31, 2015-$15.95M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$1.72M–
Q1 FY2026Mar 31, 2026-$1.80M–
Q4 FY2025Dec 31, 2025-$10.23M–
Q3 FY2025Sep 30, 2025-$7.24M–
Q2 FY2025Jun 30, 2025-$11.03M–
Q1 FY2025Mar 31, 2025-$10.67M–
Q4 FY2024Dec 31, 2024-$9.46M–
Q3 FY2024Sep 30, 2024-$9.99M–
Q2 FY2024Jun 30, 2024-$9.61M–
Q1 FY2024Mar 31, 2024-$11.93M–
Q4 FY2023Dec 31, 2023-$9.62M–
Q3 FY2023Sep 30, 2023-$8.76M–
Q2 FY2023Jun 30, 2023-$9.60M–
Q1 FY2023Mar 31, 2023-$11.68M–
Q4 FY2022Dec 31, 2022-$10.25M–
Q3 FY2022Sep 30, 2022-$14.57M–
Q2 FY2022Jun 30, 2022-$25.97M–
Q1 FY2022Mar 31, 2022-$30.91M–
Q4 FY2021Dec 31, 2021-$46.82M–
Q3 FY2021Sep 30, 2021-$26.07M–
Q2 FY2021Jun 30, 2021-$29.05M–
Q1 FY2021Mar 31, 2021-$28.31M–
Q4 FY2020Dec 31, 2020-$28.98M–
Q3 FY2020Sep 30, 2020-$25.84M–
Q2 FY2020Jun 30, 2020-$21.28M–
Q1 FY2020Mar 31, 2020-$20.13M–
Q4 FY2019Dec 31, 2019-$20.20M–
Q3 FY2019Sep 30, 2019-$21.57M–
Q2 FY2019Jun 30, 2019-$22.41M–
Q1 FY2019Mar 31, 2019-$24.05M–
Q4 FY2018Dec 31, 2018-$23.57M–
Q3 FY2018Sep 30, 2018-$15.50M–
Q2 FY2018Jun 30, 2018-$14.52M–
Q1 FY2018Mar 31, 2018-$11.14M–
Q4 FY2017Dec 31, 2017-$11.14M–
Q3 FY2017Sep 30, 2017-$9.53M–
Q2 FY2017Jun 30, 2017-$9.63M–
Q1 FY2017Mar 31, 2017-$9.57M–
Q4 FY2016Dec 31, 2016-$8.20M–
Q3 FY2016Sep 30, 2016-$9.75M–

More Kala Bio figures

See a number that looks wrong?